# RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma

> **NCT01252251** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 14 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** RAD001 (Everolimus) and Pasireotide (SOM230) LAR

## Key facts

- **NCT ID:** NCT01252251
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2017-08-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01252251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01252251, "RAD001 (Everolimus) and Pasireotide (SOM230) LAR in Patients With Advanced Uveal Melanoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01252251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*